January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
January 2012 in “Курский научно-практический вестник "Человек и его здоровье"” 5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.
4 citations
,
September 2022 in “Experimental and Сlinical Urology” 5-alpha reductase inhibitors help with benign prostatic hyperplasia but don't cure it, and more research is needed.
August 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.
22 citations
,
June 2002 in “Journal of Medicinal Chemistry” Compounds 15, 20, and 25 are strong inhibitors of human steroid 5α-reductase type 2.
1 citations
,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
These medications for BPH have known risks and may have new side effects.
48 citations
,
February 2006 in “Molecular and Cellular Endocrinology” 5α-reductase inhibitors may reduce male fertility and could be used for male contraception.
4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
37 citations
,
May 1997 in “The Journal of Clinical Endocrinology & Metabolism” MK-386 lowers DHT in blood and skin but not in semen.
February 2025 in “Iranian journal of pharmaceutical research”
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
13 citations
,
October 2005 in “Analytical Sciences” A new method was developed to measure and assess the activity and inhibition of the enzyme steroid 5α-reductase.
April 2016 in “Journal of Investigative Dermatology” FOL-005, a new substance, was found to reduce hair growth without toxicity when injected into skin, suggesting it could be used to treat excessive hair growth.
November 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Five FDA-approved drugs may help block COVID-19 virus entry.
11 citations
,
September 2008 in “European Journal of Drug Metabolism and Pharmacokinetics” Finasteride helps reduce pain and inflammation in animals.
14 citations
,
February 2011 in “Drug Metabolism and Disposition” Ketoconazole increases finasteride's effectiveness and lifespan in the body.
1 citations
,
March 2022 in “British Journal of Clinical Pharmacology” 5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
6 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.